CN101418017A - (r)-9-(2-磷酸甲氧基丙基)腺嘌呤的合成方法 - Google Patents
(r)-9-(2-磷酸甲氧基丙基)腺嘌呤的合成方法 Download PDFInfo
- Publication number
- CN101418017A CN101418017A CNA2008102026104A CN200810202610A CN101418017A CN 101418017 A CN101418017 A CN 101418017A CN A2008102026104 A CNA2008102026104 A CN A2008102026104A CN 200810202610 A CN200810202610 A CN 200810202610A CN 101418017 A CN101418017 A CN 101418017A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- propyl group
- phosphate
- methoxy propyl
- phosphorus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 15
- 229910019142 PO4 Inorganic materials 0.000 title claims description 18
- 239000010452 phosphate Substances 0.000 title claims description 18
- 230000002194 synthesizing effect Effects 0.000 title abstract description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 title 1
- 229930024421 Adenine Natural products 0.000 title 1
- 229960000643 adenine Drugs 0.000 title 1
- -1 methyl phosphono Chemical group 0.000 claims abstract description 17
- 238000006243 chemical reaction Methods 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000011782 vitamin Substances 0.000 claims description 36
- 229940088594 vitamin Drugs 0.000 claims description 36
- 229930003231 vitamin Natural products 0.000 claims description 36
- 235000013343 vitamin Nutrition 0.000 claims description 36
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 7
- JLHMVTORNNQCRM-UHFFFAOYSA-O ethylphosphanium Chemical compound CC[PH3+] JLHMVTORNNQCRM-UHFFFAOYSA-O 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 239000011574 phosphorus Substances 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- 238000010189 synthetic method Methods 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 claims description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 claims description 2
- PZHNNJXWQYFUTD-UHFFFAOYSA-N phosphorus triiodide Chemical compound IP(I)I PZHNNJXWQYFUTD-UHFFFAOYSA-N 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 abstract 2
- MJZYTEBKXLVLMY-RXMQYKEDSA-N (2r)-1-(6-aminopurin-9-yl)propan-2-ol Chemical compound N1=CN=C2N(C[C@H](O)C)C=NC2=C1N MJZYTEBKXLVLMY-RXMQYKEDSA-N 0.000 abstract 1
- GCOFRXOOFANVPB-SNVBAGLBSA-N 9-[(2r)-2-(diethoxyphosphorylmethoxy)propyl]purin-6-amine Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCC)OCC)C=NC2=C1N GCOFRXOOFANVPB-SNVBAGLBSA-N 0.000 abstract 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 238000009413 insulation Methods 0.000 description 6
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- 229960004556 tenofovir Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 239000005051 trimethylchlorosilane Substances 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124977 antiviral medication Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical class BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102026104A CN101418017B (zh) | 2008-11-12 | 2008-11-12 | (r)-9-(2-磷酸甲氧基丙基)腺嘌呤的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102026104A CN101418017B (zh) | 2008-11-12 | 2008-11-12 | (r)-9-(2-磷酸甲氧基丙基)腺嘌呤的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101418017A true CN101418017A (zh) | 2009-04-29 |
CN101418017B CN101418017B (zh) | 2011-07-20 |
Family
ID=40629033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008102026104A Expired - Fee Related CN101418017B (zh) | 2008-11-12 | 2008-11-12 | (r)-9-(2-磷酸甲氧基丙基)腺嘌呤的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101418017B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102219805A (zh) * | 2011-03-10 | 2011-10-19 | 苏州腾龙生物医药技术有限公司 | 一种新型的泰诺福韦生产工艺 |
CN103641857A (zh) * | 2013-12-20 | 2014-03-19 | 石药集团中诺药业(石家庄)有限公司 | 一种替诺福韦新晶型及其制备方法 |
CN103917550A (zh) * | 2011-11-16 | 2014-07-09 | 劳拉斯实验室私人有限公司 | 用于制备替诺福韦的方法 |
CN104530129A (zh) * | 2014-03-26 | 2015-04-22 | 广东东阳光药业有限公司 | 制备(r)-9-(2-磷酸甲氧基丙基)腺嘌呤的方法 |
CN105859781A (zh) * | 2016-05-03 | 2016-08-17 | 荆门市帅邦化学科技有限公司 | 一种泰诺福韦的产业化生产工艺 |
US9908908B2 (en) | 2012-08-30 | 2018-03-06 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Tenofovir prodrug and pharmaceutical uses thereof |
CN111961081A (zh) * | 2020-10-20 | 2020-11-20 | 北京鑫开元医药科技有限公司 | 一种(r)-2-(2-磷酸甲氧基丙基)-腺嘌呤的制备方法 |
CN113249241A (zh) * | 2021-06-21 | 2021-08-13 | 奥锐特药业(天津)有限公司 | 一种酿酒酵母蛋白酶缺失菌株的构建及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733788A (en) * | 1996-07-26 | 1998-03-31 | Gilead Sciences, Inc. | PMPA preparation |
CN100567315C (zh) * | 2005-12-19 | 2009-12-09 | 北京美倍他药物研究有限公司 | 无环核苷膦酸的前体药物 |
-
2008
- 2008-11-12 CN CN2008102026104A patent/CN101418017B/zh not_active Expired - Fee Related
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102219805A (zh) * | 2011-03-10 | 2011-10-19 | 苏州腾龙生物医药技术有限公司 | 一种新型的泰诺福韦生产工艺 |
CN103917550A (zh) * | 2011-11-16 | 2014-07-09 | 劳拉斯实验室私人有限公司 | 用于制备替诺福韦的方法 |
CN103917550B (zh) * | 2011-11-16 | 2016-08-24 | 劳拉斯实验室私人有限公司 | 用于制备替诺福韦的方法 |
US9908908B2 (en) | 2012-08-30 | 2018-03-06 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Tenofovir prodrug and pharmaceutical uses thereof |
CN103641857A (zh) * | 2013-12-20 | 2014-03-19 | 石药集团中诺药业(石家庄)有限公司 | 一种替诺福韦新晶型及其制备方法 |
CN104530129A (zh) * | 2014-03-26 | 2015-04-22 | 广东东阳光药业有限公司 | 制备(r)-9-(2-磷酸甲氧基丙基)腺嘌呤的方法 |
CN105859781A (zh) * | 2016-05-03 | 2016-08-17 | 荆门市帅邦化学科技有限公司 | 一种泰诺福韦的产业化生产工艺 |
CN111961081A (zh) * | 2020-10-20 | 2020-11-20 | 北京鑫开元医药科技有限公司 | 一种(r)-2-(2-磷酸甲氧基丙基)-腺嘌呤的制备方法 |
CN111961081B (zh) * | 2020-10-20 | 2021-03-09 | 北京鑫开元医药科技有限公司 | 一种(r)-2-(2-磷酸甲氧基丙基)-腺嘌呤的制备方法 |
CN113249241A (zh) * | 2021-06-21 | 2021-08-13 | 奥锐特药业(天津)有限公司 | 一种酿酒酵母蛋白酶缺失菌株的构建及其应用 |
CN113249241B (zh) * | 2021-06-21 | 2021-10-15 | 奥锐特药业(天津)有限公司 | 一种酿酒酵母蛋白酶缺失菌株的构建及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101418017B (zh) | 2011-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101418017B (zh) | (r)-9-(2-磷酸甲氧基丙基)腺嘌呤的合成方法 | |
CN103360425A (zh) | 替诺福韦酯及其富马酸盐的合成方法 | |
CN104327119A (zh) | 磷酸泰地唑胺的制备方法 | |
CN107021984B (zh) | 一种taf核苷衍生物的制备方法及其中间体 | |
CN104230992A (zh) | 一种高纯度富马酸泰诺福韦酯的制备方法 | |
CN104817593B (zh) | 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺 | |
CN104610360A (zh) | 一种富马酸替诺福韦二吡呋酯的制备方法 | |
CN108101942B (zh) | 半富马酸替诺福韦艾拉酚胺生产中潜在杂质的合成方法 | |
CN106699814A (zh) | 一种阿德福韦酯结晶物的制备方法 | |
CN111205326B (zh) | 一种绿色环保的泰诺福韦制备方法 | |
EP2780348B1 (en) | Process for the preparation of tenofovir | |
CN105622671A (zh) | 一种可工业化大生产富马酸替诺福韦二吡呋酯的制备方法 | |
CN106632484A (zh) | 一种替诺福韦艾拉酚胺的制备方法 | |
CN100554274C (zh) | 一种阿德福韦酯的合成方法 | |
CN102321086A (zh) | 一种腺嘌呤的合成方法 | |
CN103435651A (zh) | 核黄素磷酸钠的合成方法及工艺 | |
CN104230987A (zh) | 一种[1-卤代-(2-丙氧基)]-甲基膦酸类化合物及其制备和应用 | |
CN104341452A (zh) | 富马酸替诺福韦酯杂质的制备方法 | |
CN101812089B (zh) | 一种阿德福韦酯化合物及其新制法 | |
CN100526321C (zh) | 一种合成阿德福韦的方法 | |
CN103804415A (zh) | 阿德福韦酯的合成方法 | |
CN106554371A (zh) | 一种富马酸替诺福韦二吡呋酯(tnf)的制备方法 | |
CN102899367B (zh) | 一种生物法和化学法结合合成泰诺福韦的方法 | |
CN109438514B (zh) | 阿德福韦酯的制备方法 | |
CN104844459A (zh) | 一种氯甲基异丙基碳酸酯的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161221 Address after: 317200 Taizhou City, Zhejiang province Tiantai Industrial Park, the eight Patentee after: Zhejiang Tiantai Aurisco Pharmaceutical Limited Address before: 200042 room 1709-1710, wisdom Plaza, No. 488 Wuning South Road, Shanghai, China Patentee before: Shanghai Aoruite International Trade Co., Ltd. Patentee before: Zhejiang Tiantai Aurisco Pharmaceutical Limited |
|
CP03 | Change of name, title or address |
Address after: 317200 Zhejiang province Tiantai County eight Longxing Industrial Park Road No. 1 Patentee after: Arcane Pharmaceutical Co., Ltd. Address before: 317200 Taizhou City, Zhejiang province Tiantai Industrial Park, the eight Patentee before: Shanghai Aurisco International Co., Ltd. |
|
CP03 | Change of name, title or address | ||
CP01 | Change in the name or title of a patent holder |
Address after: 317200 Zhejiang province Tiantai County eight Longxing Industrial Park Road No. 1 Patentee after: Arcane pharmaceuticals, Limited by Share Ltd Address before: 317200 Zhejiang province Tiantai County eight Longxing Industrial Park Road No. 1 Patentee before: Arcane Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110720 Termination date: 20201112 |
|
CF01 | Termination of patent right due to non-payment of annual fee |